Biofrontera (BFRI) Cash & Equivalents (2020 - 2025)

Biofrontera's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $6.4 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 8.38% year-over-year to $6.4 million in Q4 2025; TTM through Dec 2025 was $6.4 million, a 8.38% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, up 8.38% from the prior year.
• Cash & Equivalents improved to $6.4 million in Q4 2025 per BFRI's latest filing, from $3.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $31.9 million in Q2 2022 and bottomed at $1.3 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $4.4 million (2024), against an average of $9.8 million.
• Across the five-year window, Cash & Equivalents jumped 1502.56% in 2022 and plunged 94.2% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $24.5 million in 2021, then slipped by 29.76% to $17.2 million in 2022, then slumped by 92.2% to $1.3 million in 2023, then surged by 339.69% to $5.9 million in 2024, then rose by 8.38% to $6.4 million in 2025.
• Per Business Quant, the three latest BFRI Cash & Equivalents figures stand at $6.4 million (Q4 2025), $3.4 million (Q3 2025), and $7.2 million (Q2 2025).